Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine

Authors: Viganò, M.¹; Lampertico, P.¹; Facchetti, F.¹; Lunghi, G.²; Colombo, M.¹

Source: Journal of Viral Hepatitis, Volume 15, Number 12, December 2008 , pp. 922-924(3)

Buy & download fulltext article:

Price: $48.00 plus tax (Refund Policy)

Abstract:

Summary.

Nine patients with lamivudine-resistant chronic hepatitis B infection who had been treated with adefovir 10 mg/day and had had a suboptimal response but did not have genotypic resistance to adefovir were treated with high-dose adefovir (20 mg/day). The response to the increased dose of adefovir was compared with the response in 15 patients with a suboptimal response who did not receive an increase in the dose of adefovir. The increase in the dose of adefovir did not lead to a significant reduction in hepatitis B DNA when compared with patients maintained on the standard dose. These data suggest that increasing the dose of adefovir in patients with a suboptimal response does not lead to an improved response.

Keywords: adefovir dipivoxil; antiviral treatment; HBV DNA; hepatitis B; lamivudine resistance; suboptimal response

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1365-2893.2008.01047.x

Affiliations: 1: “A. M. and A. Migliavacca” Center for Liver Disease, 1st Division of Gastroenterology, Department of Medicine, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy 2: Division of Hygiene, IRCCS Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy

Publication date: 2008-12-01